MicroRNA-181a is elevated by 10-hydroxycamptothecin and represses lung carcinoma progression by downregulating FOXP1
作者机构：Department of Biochemistry and Molecular BiologyBinzhou Medical UniversityYantai264003China Department of Medical LaboratoryYantai Affiliated Hospital of Binzhou Medical UniversityYantai264100China
出 版 物：《BIOCELL》 (生物细胞（英文）)
年 卷 期：2022年第46卷第2期
页 面：417-431页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by the National Natural Science Foundation of China(Nos.81702296,81772281) the Shandong Science and Technology Committee(Nos.2017GSF18124,ZR2019PC019,ZR2019MH022) the Health Commission of Shandong Province(Nos.2017WS737,2019KJK014) the Shandong Province Taishan Scholar Project(No.ts201712067)
主 题：microRNA-181a 10-hydroxycamptothecin Angiogenesis Lung carcinoma
摘 要：Tumor progression is usually characterized by proliferation,migration,and angiogenesis,which is essential for supplying both nutrients and oxygen to the tumor ***,targeting angiogenesis has been considered a promising therapeutic strategy for cancer prevention and *** the present study,we demonstrated that in addition to suppressing lung cancer cell proliferation and migration in vitro,10-hydroxycamptothecin(10-HCPT)is also capable of inhibiting angiogenesis in vivo with a miR-181a-dependent ***,by upregulating miR-181a,which in turn downregulating FOXP1,10-HCPT can inhibit the PI3K/Akt/ERK signaling pathwaymediated ***,reduced levels of miR-181a have been found in both lung cancer cell lines and xenograft with concurrently elevated levels of FOXP1,VEGF,bFGF,and *** with the findings from the in vitro experiments,miR-181a impairs neovascularization in our xenograft *** summary,our findings have not only established the anti-oncogenic role of miR-181a in lung cancer angiogenesis but also suggest that 10-HCPT could be a potential therapeutic reagent for lung cancer treatment.
维普期刊数据库